Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: J Clin Lipidol. 2020 Sep 4;14(6):850–858. doi: 10.1016/j.jacl.2020.08.012

Figure 1.

Figure 1.

Skin xanthomas and confirmation of LpX in the patient. A. The regression of skin xanthomas after treatment (20 weeks of regular biweekly plasmapheresis therapy), compared with the patient’s first presentation in Oct 2017. B. Plasma samples from a control subject and the LpX patient before (Jan 2018) and after treatment (May 2018). C. Plasma lipoprotein electrophoresis showing some typical features of LpX from the patient’s plasma before treatment and recovery of the β-lipoprotein band after treatment.